

**APC anti-human CD135 (Flt-3/Flk-2)**

**Catalog # / Size:** 2166540 / 100 tests  
2166535 / 25 tests

**Clone:** BV10A4H2

**Isotype:** Mouse IgG1,  $\kappa$


**Immunogen:** BV-173 pro-B cell line

**Reactivity:** Human

**Preparation:** The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions. The solution is free of unconjugated APC and unconjugated antibody.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).

**Concentration:** Lot-specific



Human pre-B cell line REH stained with BV10A4H2 APC

**Applications:**

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. **Test size products are transitioning from 20 microL to 5 microL per test.** Please check your vial or your CoA to find the suggested use of this reagent per million cells in 100 microL staining volume or per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

**Description:** CD135 is a 130-160 kD type III tyrosine kinase receptor expressed on CD34<sup>+</sup> hematopoietic stem cells, myelomonocytic progenitors, primitive B cell progenitors, and thymocytes. CD135 is also expressed on malignant hematopoietic cells including AML, ALL and CML-BC. CD135, also known as FMS-like tyrosine kinase-3, FLT3, STK-1, and Flk-2, is a growth factor receptor that binds the FLT3 ligand to promote the growth and differentiation of primitive hematopoietic cells. The intracytoplasmic domain of CD135 is modified by phosphorylation and has been shown to interact with Grb2, SOCS1, VAV1, and Shc.

**Antigen References:**

1. Rappold I, *et al.* 1997. *Blood* 90:111.
2. Rosnet O, *et al.* 1996. *Acta Haematol.* 95:218.
3. Rosnet O, *et al.* 1996. *Leukemia* 10:238.
4. Bertho JM, *et al.* 2000. *Scand. J.*